Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Acute intermittent porphyria


Other Names for this Disease
  • AIP
  • Porphobilinogen deaminase deficiency
  • PBGD deficiency
  • Uroporphyrinogen synthase deficiency
  • UPS deficiency
Related Diseases
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Your Question

My daughter may have acute intermittent porphyria. How is this condition diagnosed?

Our Answer

We have identified the following information that we hope you find helpful. If you still have questions, please contact us.

What is acute intermittent porphyria (AIP)?

Acute intermittent porphyria (AIP) is one of the liver (hepatic) porphyrias. AIP is caused by low levels of porphobilinogen deaminase (PBGD), an enzyme also often called hydroxymethylbilane synthase. The low levels of PBGD are generally not sufficient to cause symptoms; however, activating factors such as hormones, drugs, and dietary changes may trigger symptoms. Although most individuals with AIP never develop symptoms, symptomatic individuals typically present with abdominal pain with nausea. Treatment is dependent on the symptoms.[1] 
Last updated: 11/11/2015

What are the signs and symptoms of acute intermittent porphyria (AIP)?

Some people who inherit the gene for AIP never develop symptoms and are said to have "latent" AIP. Those individuals that present with symptoms usually do so after puberty, probably because of hormonal influences, although other activating factors include: alcohol, drugs (e.g., barbiturates, steroids, sulfa-containing antibiotics), chemicals, smoking, reduced caloric intake, stress, and travel. Symptoms usually last several days, but attacks for which treatment is not received promptly may last weeks or months.[2]

Abdominal pain, which is associated with nausea and can be severe, is the most common symptom and usually the first sign of an attack.[1][2]

Other symptoms may include [1][2]:

• Gastrointestinal issues (e.g., nausea, vomiting, constipation, diarrhea, abdominal distention, ileus)
• Urinary tract issues (e.g., urinary retention, urinary incontinence, or dysuria)
• Neurological issues (e.g., muscle weakness in the arms or legs, paralysis)
• Psychiatric issues (e.g., insomnia, hysteria, anxiety, apathy or depression, phobias, psychosis, agitation, delirium, somnolence, or coma)

Individuals with AIP have an increased risk of developing hepatocellular carcinoma; some develop kidney failure.[2]
Last updated: 11/12/2015

What causes acute intermittent porphyria (AIP)?

AIP is caused by the deficiency of an enzyme called porphobilinogen deaminase (PBGD), also known as hydroxymethylbilane synthase (HMBS) and formerly known as uroporphyrinogen I-synthase.[1] The deficiency of PBGD is caused by a mutation in the HMBS gene. The HMBS gene is the only gene known to be associated with AIP.[2] However, the deficiency of PBGD alone is not enough to cause AIP. Other activating factors (e.g., hormones, drugs, dietary changes) must also be present.[1] 
Last updated: 11/12/2015

How is acute intermittent porphyria (AIP) diagnosed?

Diagnosis of AIP is suspected in individuals with otherwise unexplained severe, acute abdominal pain without physical signs.[2] The finding of increased levels of delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) in urine establishes that one of the acute porphyrias is present. If PBGD is deficient in normal red blod cells, the diagnosis of AIP is established.[1] The diagnosis is confirmed in individuals with a disease-causing mutation in the HMBS gene, the only gene known to be associated with AIP, which encodes the erythrocyte hydroxymethylbilane synthase enzyme. Molecular genetic testing of the HMBS gene detects more than 98% of affected individuals and is available in clinical laboratories.[2] To obtain a list of clinical laboratories offering genetic testing for AIP, click here.
Last updated: 11/12/2015

How might acute intermittent porphyria (AIP) be treated?

Treatment of AIP may vary based on the trigger of the attack and the symptoms present. Treatment may include stopping medications that cause or worsen the symptoms, treating any infections which may be present, administration of pain medication, monitoring fluid balance and/or correcting electrolyte disturbances, monitoring neurologic status and administering respiratory support. Mild attacks can be manged with increased caloric intake and fluid replacement. Recurrent acute attacks should be managed by a porphyria specialist.[2] Hospitalization is often necessary.[1]  Panhematin, an intravenous medication used to correct heme deficiency, may also be prescribed.[3] More detailed information about the use of Panhematin for the treatment of AIP can be found by clicking here.
Last updated: 11/11/2015

References
Other Names for this Disease
  • AIP
  • Porphobilinogen deaminase deficiency
  • PBGD deficiency
  • Uroporphyrinogen synthase deficiency
  • UPS deficiency
Related Diseases
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.